P&G Intrinsa Need For Longer-Term Safety Data To Be Examined By Reproductive Cmte.
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA will ask committee whether Intrinsa testosterone patch needs more safety data in women receiving estrogen prior to approval. Procter & Gamble is proposing a pharmacovigilance study to follow emerging adverse events with the female sexual dysfunction drug.